Treatment of Geographic Atrophy by the Topical Administration of OT-551: Results of a Phase II Clinical Trial

Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Investigative ophthalmology & visual science (Impact Factor: 3.4). 12/2010; 51(12):6131-9. DOI: 10.1167/iovs.10-5637
Source: PubMed


To investigate the safety and preliminary efficacy of OT-551, a disubstituted hydroxylamine with antioxidant properties, for the treatment of geographic atrophy (GA), the advanced atrophic form of age-related macular degeneration (AMD).
The study was a single-center, open-label phase II trial, enrolling 10 participants with bilateral GA. Topical 0.45% OT-551 was administered in one randomly assigned eye three times daily for 2 years. Safety measures were assessed by complete ophthalmic examination, fundus photography, and review of symptoms. The primary efficacy outcome measure was the change in best corrected visual acuity at 24 months. Secondary efficacy measures included changes in area of GA, contrast sensitivity, microperimetry measurements, and total drusen area from baseline.
Study drug was well tolerated and was associated with few adverse events. The mean change in BCVA at 2 years was +0.2 ± 13.3 letters in the study eyes and -11.3 ± 7.6 letters in fellow eyes (P = 0.0259). However, no statistically significant differences were found between the study and fellow eyes for all other secondary outcome measures.
OT-551 was well tolerated by study participants and was not associated with any serious adverse effects. Efficacy measurements in this small study indicate a possible effect in maintaining visual acuity. However, the absence of significant effects on other outcomes measures in this study suggests that OT-551, in the current concentration and mode of delivery, may have limited or no benefit as a treatment for GA ( number, NCT00306488).

Download full-text


Available from: Denise Cunningham, Feb 10, 2014
18 Reads
  • Source
    • "Age-related macular degeneration (AMD) is a global epidemic with an estimated worldwide prevalence of 30 to 50 million [1], and a leading cause of blindness in people aged over 65 (reviewed in [2]). While anti-vascular endothelial growth factor (VEGF) therapy has proved to be of benefit for neovascular or ‘wet’ AMD [3], there are presently no treatments that mitigate progression of photoreceptor loss in the more common atrophic or ‘dry’ form of AMD [4]. Although the pathogenesis of AMD is a complex multifactorial process, the recent discovery of a direct association of complement activation with the incidence of AMD has firmly established inflammation as an important factor mediating its pathogenesis [5,6]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim Complement activation is associated with the pathogenesis of age-related macular degeneration (AMD). We aimed to investigate whether 670-nm light treatment reduces the propagation of complement in a light-induced model of atrophic AMD. Methods Sprague–Dawley (SD) rats were pretreated with 9 J/cm2 670-nm light for 3 minutes daily over 5 days; other animals were sham treated. Animals were exposed to white light (1,000 lux) for 24 h, after which animals were kept in dim light (5 lux) for 7 days. Expression of complement genes was assessed by quantitative polymerase chain reaction (qPCR), and immunohistochemistry. Counts were made of C3-expressing monocytes/microglia using in situ hybridization. Photoreceptor death was also assessed using outer nuclear layer (ONL) thickness measurements, and oxidative stress using immunohistochemistry for 4-hydroxynonenal (4-HNE). Results Following light damage, retinas pretreated with 670-nm light had reduced immunoreactivity for the oxidative damage maker 4-HNE in the ONL and outer segments, compared to controls. In conjunction, there was significant reduction in retinal expression of complement genes C1s, C2, C3, C4b, C3aR1, and C5r1 following 670 nm treatment. In situ hybridization, coupled with immunoreactivity for the marker ionized calcium binding adaptor molecule 1 (IBA1), revealed that C3 is expressed by infiltrating microglia/monocytes in subretinal space following light damage, which were significantly reduced in number after 670 nm treatment. Additionally, immunohistochemistry for C3 revealed a decrease in C3 deposition in the ONL following 670 nm treatment. Conclusions Our data indicate that 670-nm light pretreatment reduces lipid peroxidation and complement propagation in the degenerating retina. These findings have relevance to the cellular events of complement activation underling the pathogenesis of AMD, and highlight the potential of 670-nm light as a non-invasive anti-inflammatory therapy.
    Journal of Neuroinflammation 11/2012; 9(1):257. DOI:10.1186/1742-2094-9-257 · 5.41 Impact Factor
  • Source
    • "Only dietary supplements are available to treat dry type AMD. Clinical trials with Othera Pharmaceuticals’ antioxidant eye drops OT551 for dry type showed promise in phase 1 trials, but failed to demonstrate any benefit greater than from placebo in phase 2 trials [5]. Recently, the Federal Drug Administration approved “Center Sight”—a tiny implantable miniature telescope (IMT). "
    [Show abstract] [Hide abstract]
    ABSTRACT: We describe the synthesis and use of an efficient nano carrier molecule for retinal delivery of a nano chitosan peptide that has potential application for treating age-related macular degeneration (AMD). We chose serine-threonine-tyrosine as the peptide sequence because it is well known to act as a transduction signaling agent within and between retinal pigmented epithelium cells. A nanoformulation of a water-soluble chitosan conjugated with a peptide (serine-threonine-tyrosine) was synthesized by a method developed in our laboratory and characterized with dynamic light scattering, zeta potential, transmission electron microscopy, nuclear magnetic resonance, and Fourier transform infrared spectroscopy. The in vitro efficacy of the formulation was evaluated in retinal cells with confocal microscopy by studying the formulation's action on tyrosine kinase activity. The conjugated nano chitosan peptide showed evidence of tyrosine kinase activity as seen by fluorescent signals under confocal microscopy, while nano chitosan or peptide alone did not show such activity. Conjugated nano chitosan peptide may promote binding and engulfment. This molecule is an excellent carrier for retinal drug delivery and has the potential to treat age-related macular degeneration.
    Molecular vision 09/2012; 18:2300-8. · 1.99 Impact Factor
  • Source
    • "It was found to be effective in maintaining visual acuity with no serious side effects. However, limited beneficiary effect in treating geographic atrophy suggests the requirement of evaluating its efficacy at high doses [127]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Advancements in the field and rising interest among pharmaceutical researchers have led to the development of new molecules with enhanced therapeutic activity. Design of new drugs which can target a particular pathway and/or explore novel targets is of immense interest to ocular pharmacologists worldwide. Delivery of suitable pharmacologically active agents at proper dose (within the therapeutic window) to the target tissues without any toxicity to the healthy ocular tissues still remain an elusive task. Moreover, the presence of static and dynamic barriers to drug absorption including the corneal epithelium (lipophilic), corneal and scleral stroma (hydrophilic), conjunctival lymphatics, choroidal vasculature and the blood-ocular barriers also pose a significant challenge for achieving therapeutic drug concentrations at the target site. Although many agents are currently available, new compounds are being introduced for treating various ocular diseases. Deeper understanding of the etiology and complex mechanisms associated with the disease condition would aid in the development of potential therapeutic candidates. Novel small molecules as well as complex biotechnology derived macromolecules with superior efficacy, safety and tolerability are being developed. Therefore, this review article provides an overview of existing drugs, treatment options, advances in emerging therapeutics and related recent patents for the treatment of ocular disorders such as glaucoma, age related macular degeneration (AMD) and uveitis.
Show more